Literature DB >> 9212230

Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation.

R P Huang1, Y Fan, I de Belle, C Niemeyer, M M Gottardis, D Mercola, E D Adamson.   

Abstract

We have examined several types of tumor cell lines and shown that they invariably expressed little or no Egr-1, in contrast to their normal counterparts. We have previously shown that the expression of exogenous Egr-1 in human breast and other tumor cells markedly reduces transformed growth and tumorigenicity. We therefore hypothesized that the loss of Egr-1 expression plays a role in transformation. All human and mouse breast cancer cell lines and tumors examined had reduced Egr-1 expression compared with their normal counterparts. Reduced Egr-1 expression was also observed in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors, and this level increased to normal levels in tumors that regressed after tamoxifen treatment. We concluded, therefore, that loss of Egr-1 expression may play a role in the deregulation of normal growth in the tumorigenic process and that Egr-1 acts as a tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212230     DOI: 10.1002/(sici)1097-0215(19970703)72:1<102::aid-ijc15>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  73 in total

1.  Genetic background-dependent role of Egr1 for eyelid development.

Authors:  Jangsuk Oh; Yujuan Wang; Shida Chen; Peng Li; Ning Du; Zu-Xi Yu; Donna Butcher; Tesfay Gebregiorgis; Erin Strachan; Ordan J Lehmann; Brian P Brooks; Chi-Chao Chan; Warren J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-04       Impact factor: 11.205

2.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

3.  Transcriptional Regulation of EGR1 by EGF and the ERK Signaling Pathway in Prostate Cancer Cells.

Authors:  Jennifer Gregg; Gail Fraizer
Journal:  Genes Cancer       Date:  2011-09

Review 4.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

5.  Role of promoter DNA sequence variations on the binding of EGR1 transcription factor.

Authors:  David C Mikles; Brett J Schuchardt; Vikas Bhat; Caleb B McDonald; Amjad Farooq
Journal:  Arch Biochem Biophys       Date:  2014-03-18       Impact factor: 4.013

6.  Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

Authors:  Martín C Abba; Yuhui Hu; Carla C Levy; Sally Gaddis; Frances S Kittrell; Jamal Hill; Reid P Bissonnette; Powel H Brown; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

7.  ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.

Authors:  Seong-Ho Lee; Jae Hoon Bahn; Chang Kyoung Choi; Nichelle C Whitlock; Anthony E English; Stephen Safe; Seung Joon Baek
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

8.  Enthalpic factors override the polyelectrolyte effect in the binding of EGR1 transcription factor to DNA.

Authors:  David C Mikles; Vikas Bhat; Brett J Schuchardt; Caleb B McDonald; Amjad Farooq
Journal:  J Mol Recognit       Date:  2014-02       Impact factor: 2.137

9.  Trisomy 12 CLLs progress through NOTCH1 mutations.

Authors:  V Balatti; S Lerner; L Rizzotto; L Z Rassenti; A Bottoni; A Palamarchuk; L Cascione; H Alder; M J Keating; T J Kipps; Y Pekarsky; C M Croce
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528

10.  Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.

Authors:  Alexandra A Mourad-Zeidan; Vladislava O Melnikova; Hua Wang; Avraham Raz; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.